Washington : Scientists have found that a new drug in early-stage tests treated tumours in 38 per cent of patients with melanoma, the deadliest form of skin cancer, reports PTI.
The results are from the first clinical trial of the drug lambrolizumab (MK3475), which was discovered and developed by global health care providerMerck. Researchers at the University of California, Los Angeles’s Jonsson Comprehensive Cancer analysed 135 patients with advanced metastatic melanoma who were divided into three groups with different treatment regimens.
Overall, 38 per cent of patients taking lambrolizumab saw confirmed improvement of their cancer across all dose levels.
Of those taking the lowest dose of lambrolizumab, 25 per cent showed improvement, while 52 per cent of those who received the highest dose improved.
The rate of any tumour response across all patients was 77 per cent.